Your browser doesn't support javascript.
loading
The BCKDH kinase inhibitor BT2 promotes BCAA disposal and mitochondrial proton leak in both insulin-sensitive and insulin-resistant C2C12 myotubes.
Rivera, Caroline N; Smith, Carly E; Draper, Lillian V; Kee, Madison E; Cook, Norah E; McGovern, Macey R; Watne, Rachel M; Wommack, Andrew J; Vaughan, Roger A.
  • Rivera CN; Department of Health and Human Performance, High Point University, High Point, North Carolina, USA.
  • Smith CE; Department of Health and Human Performance, High Point University, High Point, North Carolina, USA.
  • Draper LV; Department of Health and Human Performance, High Point University, High Point, North Carolina, USA.
  • Kee ME; Department of Health and Human Performance, High Point University, High Point, North Carolina, USA.
  • Cook NE; Department of Health and Human Performance, High Point University, High Point, North Carolina, USA.
  • McGovern MR; Department of Health and Human Performance, High Point University, High Point, North Carolina, USA.
  • Watne RM; Department of Chemistry, High Point University, High Point, North Carolina, USA.
  • Wommack AJ; Department of Chemistry, High Point University, High Point, North Carolina, USA.
  • Vaughan RA; Department of Health and Human Performance, High Point University, High Point, North Carolina, USA.
J Cell Biochem ; 125(3): e30520, 2024 03.
Article en En | MEDLINE | ID: mdl-38226684
ABSTRACT
Elevated circulating branched-chain amino acids (BCAAs) have been correlated with the severity of insulin resistance, leading to recent investigations that stimulate BCAA metabolism for the potential benefit of metabolic diseases. BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid), an inhibitor of branched-chain ketoacid dehydrogenase kinase, promotes BCAA metabolism by enhancing BCKDH complex activity. The purpose of this report was to investigate the effects of BT2 on mitochondrial and glycolytic metabolism, insulin sensitivity, and de novo lipogenesis both with and without insulin resistance. C2C12 myotubes were treated with or without low or moderate levels of BT2 with or without insulin resistance. Western blot and quantitative real-time polymerase chain reaction were used to assess protein and gene expression, respectively. Mitochondrial, nuclei, and lipid content were measured using fluorescent staining and microscopy. Cell metabolism was assessed via oxygen consumption and extracellular acidification rate. Liquid chromatography-mass spectrometry was used to quantify BCAA media content. BT2 treatment consistently promoted mitochondrial uncoupling following 24-h treatment, which occurred largely independent of changes in expressional profiles associated with mitochondrial biogenesis, mitochondrial dynamics, BCAA catabolism, insulin sensitivity, or lipogenesis. Acute metabolic studies revealed a significant and dose-dependent effect of BT2 on mitochondrial proton leak, suggesting BT2 functions as a small-molecule uncoupler. Additionally, BT2 treatment consistently and dose-dependently reduced extracellular BCAA levels without altering expression of BCAA catabolic enzymes or pBCKDHa activation. BT2 appears to act as a small-molecule mitochondrial uncoupler that promotes BCAA utilization, though the interplay between these two observations requires further investigation.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Resistencia a la Insulina / Insulina Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Resistencia a la Insulina / Insulina Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article